Dan Li

US Patent:

8036735, Oct 11, 2011

Filed:

Aug 8, 2007

Appl. No.:

11/835812

Inventors:

Shelley M. Cazares - Washington DC, US
Haresh G. Sachanandani - Shoreview MN, US
Benjamin Ettori - Pittsburgh PA, US
Dan Li - Shoreview MN, US
Yanting Dong - Shoreview MN, US

Assignee:

Cardiac Pacemakers, Inc. - St. Paul MN

International Classification:

A61B 5/044
A61B 5/0452

US Classification:

600523, 600510, 600522

Abstract:

A system evaluates the performance of an implantable medical device, such as by using a remote external server and a user interface and stored historical physiological data of a population of congestive heart failure (CHF) patients. A processor is coupled to a patient data storage device to apply multiple algorithm variations against the same implantable physiological data from the patient to produce corresponding resulting CHF indicators. The user interface includes a display that is configured to display to a user information allowing comparison between the resulting CHF indicators from the multiple algorithm variations. The display also includes a population data selector to permit the user to select physiological data from a population that includes a different set of one or more patients or physiological data collected over a period of time from the patient. This permits optimization of an algorithm parameter or selection of a best performing algorithm.

US Patent:

8271088, Sep 18, 2012

Filed:

Jul 20, 2010

Appl. No.:

12/839913

Inventors:

Shelley M. Cazares - Washington DC, US
Dan Li - Shoreview MN, US
Jonathan Kwok - Holmdel NJ, US

Assignee:

Cardiac Pacemakers, Inc. - St. Paul MN

International Classification:

A61N 1/362

US Classification:

607 32

Abstract:

This document discusses, among other things, methods and systems for facilitating automated device programming at changeout. A method comprises receiving, from a first device, physiological data at a temporary storage device; and processing the received physiological data, wherein the processing includes determining if a first signal processing function was used by the first device and substantially offsetting the first signal processing function if the first signal processing function was used by the first device; and processing the resultant physiological data to be compatible with a second device. The method further comprising providing the processed resultant physiological data to the second device.

US Patent:

8521289, Aug 27, 2013

Filed:

Sep 5, 2012

Appl. No.:

13/603934

Inventors:

Shelley M. Cazares - Washington DC, US
Dan Li - Shoreview MN, US
Jonathan Kwok - Holmdel NJ, US

Assignee:

Cardiac Pacemakers, Inc. - St. Paul MN

International Classification:

A61N 1/362

US Classification:

607 32

Abstract:

This document discusses, among other things, methods and systems for facilitating automated device programming at changeout. A method comprises receiving, from a first device, physiological data at a temporary storage device; and processing the received physiological data, wherein the processing includes determining if a first signal processing function was used by the first device and substantially offsetting the first signal processing function if the first signal processing function was used by the first device; and processing the resultant physiological data to be compatible with a second device. The method further comprising providing the processed resultant physiological data to the second device.

US Patent:

20050181374, Aug 18, 2005

Filed:

Jan 5, 2004

Appl. No.:

10/752079

Inventors:

Scott Friedman - Scarsdale NY, US
Dan Li - New York NY, US
Goutham Narla - New York NY, US
John Martignetti - Chappaqua NY, US
Karen Heath - Madrid, ES

Assignee:

Mount Sinai School of Medicine of New York University - New York NY

International Classification:

C12Q001/68
G01N033/53
G01N033/567

US Classification:

435006000, 435007200

Abstract:

The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.

US Patent:

20110059899, Mar 10, 2011

Filed:

Apr 28, 2010

Appl. No.:

12/769595

Inventors:

Scott Friedman - Scarsdale NY, US
Dan Li - Arlington MA, US
Goutham Narla - New Rochelle NY, US
John Martignetti - Chappaqua NY, US
Karen Heath - Madrid, ES

Assignee:

Mount Sinai School of Medicine of New York University - New York NY

International Classification:

A61K 38/17
A61K 31/7088
A61P 35/00
C12Q 1/68
G01N 33/53
C12Q 1/48
C12Q 1/28
C12N 5/02
C12N 15/63

US Classification:

514 193, 514 44 R, 435 6, 435 71, 435 15, 435 28, 435375, 4353201

Abstract:

The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.

US Patent:

20220380471, Dec 1, 2022

Filed:

Oct 21, 2020

Appl. No.:

17/770940

Inventors:

- Bethesda MD, US
Ruixue Wang - Bethesda MD, US
Brad St. Croix - Frederick MD, US
Dan Li - Rockville MD, US

Assignee:

The U.S.A., as represented by the Secretary, Department of Health and Human Services - Bethesda MD

International Classification:

C07K 16/28
A61P 35/00
G01N 33/574

Abstract:

Single-domain monoclonal antibodies that specifically bind B7H3 (also known as CD276) are described. The single-domain antibodies include camel VH and rabbit VH domain nanobodies selected from phage display libraries. Chimeric antigen receptors (CARs) and other antibody conjugates targeted to B7H3 are also described. The single-domain antibodies and conjugates thereof can be used for the diagnosis and treatment of B7H3 expressing solid tumors.

US Patent:

20210371542, Dec 2, 2021

Filed:

Nov 7, 2018

Appl. No.:

16/762459

Inventors:

- Bethesda MD, US
Nan Li - Laurel MD, US
Dan Li - Bethesda MD, US

Assignee:

The U.S.A., as represented by the Secretary, Department of Health and Human Services - Bethesda MD

International Classification:

C07K 16/30
C07K 14/715
C07K 14/71
C07K 14/705
C07K 14/725
A61K 35/17
A61P 35/00

Abstract:

Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8α hinge region, a CD8α transmembrane region, a 4-1BB co-stimulatory domain and a CD3ζ signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.